MX2019005736A - Composicion farmaceutica para prevenir o tratar el cancer de mama que incluye polimorfo cristalino de hexaoxido de tetraarsenico y metodo para preparar el mismo. - Google Patents

Composicion farmaceutica para prevenir o tratar el cancer de mama que incluye polimorfo cristalino de hexaoxido de tetraarsenico y metodo para preparar el mismo.

Info

Publication number
MX2019005736A
MX2019005736A MX2019005736A MX2019005736A MX2019005736A MX 2019005736 A MX2019005736 A MX 2019005736A MX 2019005736 A MX2019005736 A MX 2019005736A MX 2019005736 A MX2019005736 A MX 2019005736A MX 2019005736 A MX2019005736 A MX 2019005736A
Authority
MX
Mexico
Prior art keywords
preventing
pharmaceutical composition
breast cancer
crystalline polymorph
treating breast
Prior art date
Application number
MX2019005736A
Other languages
English (en)
Inventor
Ju Bae Ill
Lian Zenglin
Original Assignee
Chemas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemas Co Ltd filed Critical Chemas Co Ltd
Publication of MX2019005736A publication Critical patent/MX2019005736A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/36Arsenic; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/285Arsenic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01GCOMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G28/00Compounds of arsenic
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01GCOMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G28/00Compounds of arsenic
    • C01G28/005Oxides; Hydroxides; Oxyacids
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00Crystal-structural characteristics
    • C01P2002/70Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
    • C01P2002/72Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00Crystal-structural characteristics
    • C01P2002/70Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
    • C01P2002/77Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by unit-cell parameters, atom positions or structure diagrams
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00Crystal-structural characteristics
    • C01P2002/80Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70
    • C01P2002/88Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70 by thermal analysis data, e.g. TGA, DTA, DSC
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00Physical properties of inorganic compounds
    • C01P2006/80Compositional purity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)

Abstract

La presente invención se relaciona con una composición farmacéutica para prevenir o tratar el cáncer de mama la cual incluye hexaóxido de tetraarsénico en la cual un polimorfo cristalino a (AS4O6-a) de hexaóxido de tetraarsénico es 99% o mayor y con un método para producir el mismo. La composición de la presente invención exhibe excelentes efectos de inhibición de la proliferación y metástasis de células cancerosas y de este modo puede ser usada de manera útil como un agente anticáncer.
MX2019005736A 2016-11-21 2017-11-17 Composicion farmaceutica para prevenir o tratar el cancer de mama que incluye polimorfo cristalino de hexaoxido de tetraarsenico y metodo para preparar el mismo. MX2019005736A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160155228A KR101834366B1 (ko) 2016-11-21 2016-11-21 육산화사비소의 결정다형을 포함하는 유방암 예방 또는 치료용 약학 조성물 및 이의 제조방법
PCT/KR2017/013148 WO2018093215A1 (ko) 2016-11-21 2017-11-17 육산화사비소의 결정다형을 포함하는 유방암 예방 또는 치료용 약학 조성물 및 이의 제조방법

Publications (1)

Publication Number Publication Date
MX2019005736A true MX2019005736A (es) 2019-07-04

Family

ID=61726934

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005736A MX2019005736A (es) 2016-11-21 2017-11-17 Composicion farmaceutica para prevenir o tratar el cancer de mama que incluye polimorfo cristalino de hexaoxido de tetraarsenico y metodo para preparar el mismo.

Country Status (16)

Country Link
US (1) US10525079B2 (es)
EP (1) EP3542803B1 (es)
JP (1) JP6824432B2 (es)
KR (1) KR101834366B1 (es)
CN (2) CN116440161A (es)
AU (1) AU2017360701B2 (es)
BR (1) BR112019009483A2 (es)
CA (1) CA3043153C (es)
CL (1) CL2019001369A1 (es)
IL (1) IL266706B (es)
MX (1) MX2019005736A (es)
MY (1) MY197198A (es)
PH (1) PH12019501119A1 (es)
SA (1) SA519401785B1 (es)
WO (1) WO2018093215A1 (es)
ZA (1) ZA201902612B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
KR101844049B1 (ko) * 2016-12-05 2018-03-30 주식회사 케마스 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물
KR101844050B1 (ko) * 2016-12-09 2018-05-14 주식회사 케마스 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Fgfr阻害剤としての三環式複素環
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100272835B1 (ko) * 1998-05-08 2000-11-15 배일주 천연 화학물질 육산화사비소의 신규한 항종양 치료제로서의 용도 및 그 약학적 조성물
US7261906B2 (en) * 1998-05-08 2007-08-28 Ill-Ju Bae Anti-cancer therapy agent of arsenic hexoxide (As4O6) of a natural chemical substance and its pharmaceutical composition
KR100399657B1 (ko) * 2000-06-29 2003-09-29 배일주 혈관신생 억제제
CN1471925A (zh) * 2002-08-02 2004-02-04 丛繁滋 更适于硬质肿瘤直接给药的含砷组合物、制剂及制备方法
KR100483195B1 (ko) 2002-08-12 2005-04-14 배일주 육산화사비소를 유효성분으로 함유하는 사상충증예방·치료용 약제학적 조성물
KR101572529B1 (ko) 2008-11-14 2015-11-27 배일주 암 치료를 위한 육산화사비소의 병용요법
KR101100786B1 (ko) 2008-12-16 2011-12-29 (주)천지산 암에 대한 방사선 치료 증진용 조성물
KR101391148B1 (ko) 2012-03-29 2014-05-07 옥은희 면역 관련 질환 및 산화적 스트레스 관련 질환의 예방 또는 치료용 조성물
KR101755556B1 (ko) * 2016-11-18 2017-07-07 주식회사 케마스 육산화사비소의 결정다형을 포함하는 뇌암 예방 또는 치료용 약학 조성물 및 이의 제조방법

Also Published As

Publication number Publication date
CN116440161A (zh) 2023-07-18
EP3542803A4 (en) 2020-07-15
EP3542803B1 (en) 2022-12-21
JP2020503372A (ja) 2020-01-30
US10525079B2 (en) 2020-01-07
WO2018093215A1 (ko) 2018-05-24
PH12019501119A1 (en) 2019-11-25
MY197198A (en) 2023-05-31
AU2017360701A1 (en) 2019-06-20
CL2019001369A1 (es) 2020-02-21
ZA201902612B (en) 2020-11-25
US20190328780A1 (en) 2019-10-31
EP3542803A1 (en) 2019-09-25
IL266706A (en) 2019-08-29
CA3043153A1 (en) 2018-05-24
JP6824432B2 (ja) 2021-02-03
BR112019009483A2 (pt) 2019-07-30
SA519401785B1 (ar) 2021-12-14
IL266706B (en) 2022-02-01
CA3043153C (en) 2021-11-02
AU2017360701B2 (en) 2021-04-01
KR101834366B1 (ko) 2018-03-05
CN108079018A (zh) 2018-05-29

Similar Documents

Publication Publication Date Title
SA519401785B1 (ar) تركيبة صيدلانية للوقاية من سرطان الثدي أو علاجه تشتمل على متعدد أشكال بلورية لسداسي أكسيد الزرنيخ الرباعي، وطريقة لإنتاجها
SA519401787B1 (ar) تركيبة صيدلانية للوقاية من سرطان المخ أو علاجه تشتمل على متعدد أشكال بلورية لسداسي أكسيد الزرنيخ الرباعي، وطريقة لتحضيرها
PH12019501292A1 (en) Pharmaceutical composition for preventing or treating cancer, comprising tetraarsenic hexoxide crystalline polymorph
PH12019501220A1 (en) Pharmaceutical composition for preventing or treating liver cancer, comprising tetraarsenic hexoxide crystalline polymorph
MX2018012016A (es) Compuestos biciclicos.
PH12020500033A1 (en) Macrocyclic compounds and uses thereof
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2022005780A (es) Moduladores de receptores estrogenicos.
MY196836A (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
PH12015502414A1 (en) Enhancer of zeste homolog 2 inhibitors
MX2016010216A (es) Composiciones farmaceuticas solidas de antagonistas de los receptores de androgenos.
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
PH12020500072A1 (en) Heterocyclic inhibitors of atr kinase
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
MX2019013419A (es) Compuestos plaguicidas biciclicos.
MX2018016290A (es) Agente antidesgaste.
WO2019023315A3 (en) RAC INHIBITORS
PH12019500198A1 (en) Compounds and compositions and uses thereof
SA520411726B1 (ar) مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
MX2021009195A (es) Metodos y composiciones para el tratamiento del cancer.
IN2014MU00495A (es)
CR20190580A (es) Compuestos de piridina y pirazina
MX2015014036A (es) Inhibidores de metastasis.